Studies suggest that biological agents, including IL-17 inhibitors, may induce eczematous rashes through abnormal immunomodulation in the skin, presenting as skin dehydration or delayed hypersensitivity reactions (28). The gene discussed is IL17A; the disease is type IV hypersensitivity disease.